From the Journals

Testosterone Replacement Therapy and Prostate Cancer Risk


 

DISCLOSURES:

This study was funded by a consortium of testosterone manufacturers led by AbbVie Inc., with additional financial support from Endo Pharmaceuticals, Acerus Pharmaceuticals Corporation, and Upsher-Smith Laboratories. Bhasin, Lincoff, and Khera reported receiving grants and consulting and personal fees from various sources. The remaining authors disclosed no conflicts of interest.

A version of this article appeared on Medscape.com.

Pages

Recommended Reading

IVF linked to slight increase in risk of some cancers
AVAHO
Discuss compounded bioidentical hormones and cancer risk
AVAHO
No increase in breast cancer risk with fertility treatments
AVAHO
‘I did nothing wrong’: MDs used their own sperm for fertility patients
AVAHO
Although inconclusive, CV safety study of cancer therapy attracts attention
AVAHO
Link between PCOS and increased risk of pancreatic cancer?
AVAHO
Difficulty fitting family into career: Female oncologists
AVAHO
Prostate cancer drug shortage leaves some with uncertainty
AVAHO
Optimal Follow-up After Fertility-Sparing Cervical Cancer Surgery
AVAHO